CMML Prognostic Scoring Systems (from Spain and Dusseldorf)

Assess risk of progression to AML and early mortality in CMML

The global unit selector only affects unanswered questions
1.Blast Count?
2.Hemoglobin?
3.Platelets?
4.LDH?
Created by

1. Blast Count?

Created by
0/4 completed

About this Calculator

CMML is a stem cell disorder with heterogeneous clinical and pathologic features, often sharing characteristics of both myelodysplastic and myeloproliferative disorders. This study of 235 individuals registered in a German MDS Registry determined prognostic findings associated with overall survival and transformation to acute myeloid leukemia, specific to CMML. The authors identified 4 factors that were able to differentiate patients into 3 risk categories with expectant median survivals ranging from 11 months to 93 months. An alternative scoring system (from the Spanish Registry) is an option when cytogenetic studies are available.

References

Such E, Cervera J, Nomdedeu B, Pedro C, Bueno J, et al.

A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia. American Society of Hematology. New Orleans: Blood; 2009:abstract # 1750.

Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W.

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

Leukemia 1992, 6 (1): 52-9

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.